Autonomous cortisol secretion in primary aldosteronism is associated with a higher prevalence of type 2 diabetes compared to patients with normal cortisol suppression (20% vs 0.8%, P<0.0001).
Observational (n=644)
Does autonomous cortisol secretion increase the risk of impaired glucose metabolism and type 2 diabetes in patients with primary aldosteronism?
Autonomous cortisol secretion is common in primary aldosteronism and is significantly associated with impaired glucose metabolism and a higher risk of type 2 diabetes.
Absolute Event Rate: 20% vs 0.8%
p-value: p=< 0.0001
CONTEXT: Primary aldosteronism (PA) is associated with higher cardiovascular morbidity and metabolic risks. Recent studies report glucocorticoid cosecretion as a relevant phenotype of PA, which could contribute to associated risks, including type 2 diabetes mellitus (T2DM). The relationship between autonomous cortisol secretion (ACS) and glucose metabolism in PA has not been investigated. OBJECTIVE: To evaluate the prevalence of impaired glucose homeostasis in patients with PA according to cortisol cosecretion. DESIGN: We performed oral glucose tolerance tests (OGTTs) and complete testing for hypercortisolism 1-mg dexamethasone suppression test (DST), late-night salivary cortisol, 24-hour urinary free cortisol in 161 newly diagnosed patients with PA of the German Conn Registry. Seventy-six of 161 patients were reevaluated at follow-up. We compared our results to a population-based sample from the Cooperative Health Research in the Region of Augsburg (KORA)-F4 study matched to the participants with PA (3:1) by sex, age, and body mass index. RESULTS: At the time of diagnosis, 125 patients (77.6%) had a pathological response in at least one of the Cushing screening tests; T2DM was diagnosed in 6.4% of these 125 cases. Patients with a pathological DST exhibited significantly higher 2-hour plasma glucose in OGTTs and were significantly more often diagnosed with T2DM than were patients with a normal DST (20% vs 0.8%, P < 0.0001) and matched controls from the KORA study (20.6% vs 5.9%, P = 0.022). Patients with PA without ACS tended to have higher homeostatic model assessment of insulin resistance levels than did KORA control subjects (P = 0.05). CONCLUSION: ACS appears frequently in patients with PA and is associated with impaired glucose metabolism, which could increase the risk of T2DM. PA itself seems to enhance insulin resistance.
Gerards et al. (Wed,) conducted a observational in Primary aldosteronism (n=644). Autonomous cortisol secretion (pathological DST) vs. Normal DST and matched population controls was evaluated on Diagnosis of type 2 diabetes mellitus (p=< 0.0001). Autonomous cortisol secretion in primary aldosteronism is associated with a higher prevalence of type 2 diabetes compared to patients with normal cortisol suppression (20% vs 0.8%, P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: